why choose us

First received: December 24, 2022

Clinical Trial: A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults With Long COVID.

Study Status: Completed

Recruit Status: RECRUITING

Condition: Long COVID

Study Type: INTERVENTIONAL


Official Title: An Interventional Decentralized Phase 2, Randomized, Double-Blind, 2-Arm Study to Investigate the Efficacy and Safety of Orally Administered Nirmatrelvir/Ritonavir Compared With Placebo/Rito

Brief Summary: This decentralized trial is a Phase 2, 1:1 randomized, double-blind, superiority, placebo-controlled study in an anticipated 100 non-hospitalized highly symptomatic adult participants with long COVID.It seeks to determine the efficacy, safety, and tolerability of 15 days of Paxlovid (nirmatrelvir/ritonavir), an anti-viral agent, compared with placebo plus ritonavir.The hypothesis is that viral persistence contributes to long COVID in some patients and nirmatrelvir/ritonavir compared with…

Read more